Biogen, Eisai get Japanese nod for Leqembi Intravenous Infusion for Alzheimer's Disease

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI Intravenous Infusion (200 mg, 500mg, lecanemab) has been...

Related Keywords

Japan ,Tsukuba ,Ibaraki ,Japanese ,Christophera Viehbacher ,Haruo Naito ,Tsukuba Research Laboratories ,Ad Cooperative Study ,Ministry Of Health ,Clinical Dementia Rating Sum ,Daily Living Scale ,Mild Cognitive Impairment ,Clinical Trials ,New England Journal ,Chief Executive Officer ,Biogen Japan ,Marketing Authorization ,Eisai ,Biogen ,Leqembi ,Dementia ,Cognitive Impairment ,Alzheimers Disease ,